Enhancement of non-homologous end joining DNA repair capacity confers cancer cells resistance to the novel selenophene compound, D-501036

Cancer Letters

Volumn 309, Issue 1, 2011, Pages 110-118

  Yang, Yung Ning ^a,b   Chou, Kai ming ^c   Pan, Wen Yu ^b   Chen, Yih wen ^c   Tsou, Tsui Chun ^b   Yeh, Ssu Ching ^b   Cheung, Chun Hei Antonio ^b   Chen, Li Tzong ^b,d   Chang, Jang Yang ^a,b,d  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c INDIANA UNIVERSITY   (United States)

^d NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

DNA double strand breaks; Drug resistance; Selenophene

Indexed keywords

2,5 BIS(5 HYDROXYMETHYL 2 SELENIENYL) 3 HYDROXYMETHYL N METHYLPYRROLE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; D 501036; ETOPOSIDE; KU80 PROTEIN; OXALIPLATIN; PACLITAXEL; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; CANCER CELL; CANCER RESISTANCE; CONTROLLED STUDY; DNA ADDUCT; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG SENSITIVITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IC 50; NONHOMOLOGOUS END JOINING; PRIORITY JOURNAL; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; ORGANOSELENIUM COMPOUNDS; PYRROLES; UP-REGULATION; UTERINE CERVICAL NEOPLASMS;

EID: 79959836483     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.05.023     Document Type: Article

References (25)

1. Juang S.H., Lung C.C., Hsu P.C., Hsu K.S., Li Y.C., Hong P.C., Shiah H.S., Kuo C.C., Huang C.W., Wang Y.C., Huang L., Chen T.S., Chen S.F., Fu K.C., Hsu C.L., Lin M.J., Chang C.J., Ashendel C.L., Chan T.C., Chou K.M., Chang J.Y. D-501036, a novel selenophene-based triheterocycle derivative, exhibits potent in vitro and in vivo antitumoral activity which involves DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation. Mol. Cancer Ther. 2007, 6:193-202.
2. Jackson S.P., Bartek J. The DNA-damage response in human biology and disease. Nature 2009, 461:1071-1078.
3. Hoeijmakers J.H. DNA damage, aging, and cancer. N Engl. J. Med. 2009, 361:1475-1485.
4. Aravind L., Walker D.R., Koonin E.V. Conserved domains in DNA repair proteins and evolution of repair systems. Nucleic Acids Res. 1999, 27:1223-1242.
5. Fojo T., Bates S. Strategies for reversing drug resistance. Oncogene 2003, 22:7512-7523.
6. Moorehead R.A., Armstrong S.G., Rainbow A.J., Singh G. Nucleotide excision repair in the human ovarian carcinoma cell line (2008) and its cisplatin-resistant variant (C13*). Cancer Chemother. Pharmacol. 1996, 38:245-253.
7. Chen K.H., Yakes F.M., Srivastava D.K., Singhal R.K., Sobol R.W., Horton J.K., Van Houten B., Wilson S.H. Up-regulation of base excision repair correlates with enhanced protection against a DNA damaging agent in mouse cell lines. Nucleic Acids Res. 1998, 26:2001-2007.
8. Kuo C.C., Liu J.F., Shiah H.S., Ma L.C., Chang J.Y. Tamoxifen accelerates proteasomal degradation of O6-methylguanine DNA methyltransferase in human cancer cells. Int. J. Cancer 2007, 121:2293-2300.
9. Pardo B., Gomez-Gonzalez B., Aguilera A. DNA repair in mammalian cells: DNA double-strand break repair: how to fix a broken relationship. Cell Mol. Life Sci. 2009, 66:1039-1056.
10. Daley J.M., Palmbos P.L., Wu D., Wilson T.E. Nonhomologous end joining in yeast. Annu. Rev. Genet. 2005, 39:431-451.
11. Lisby M., Barlow J.H., Burgess R.C., Rothstein R. Choreography of the DNA damage response: spatiotemporal relationships among checkpoint and repair proteins. Cell 2004, 118:699-713.
12. Krogh B.O., Symington L.S. Recombination proteins in yeast. Annu. Rev. Genet. 2004, 38:233-271.
13. Slupianek A., Hoser G., Majsterek I., Bronisz A., Malecki M., Blasiak J., Fishel R., Skorski T. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol. Cell Biol. 2002, 22:4189-4201.
14. Finlay G.J., Baguley B.C., Wilson W.R. A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells. Anal. Biochem. 1984, 139:272-277.
15. Chen C.C., Chen L.T., Tsou T.C., Pan W.Y., Kuo C.C., Liu J.F., Yeh S.C., Tsai F.Y., Hsieh H.P., Chang J.Y. Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil. Br. J. Cancer 2007, 97:334-344.
16. Baumann P., West S.C. DNA end-joining catalyzed by human cell-free extracts. Proc. Natl. Acad. Sci. USA 1998, 95:14066-14070.
17. Shiah H.S., Lee W.S., Juang S.H., Hong P.C., Lung C.C., Chang C.J., Chou K.M., Chang J.Y. Mitochondria-mediated and p53-associated apoptosis induced in human cancer cells by a novel selenophene derivative, D-501036. Biochem. Pharmacol. 2007, 73:610-619.
18. Doyle L.A., Yang W., Abruzzo L.V., Krogmann T., Gao Y., Rishi A.K., Ross D.D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA 1998, 95:15665-15670.
19. Perez R.P. Cellular and molecular determinants of cisplatin resistance. Eur. J. Cancer 1998, 34:1535-1542.
20. Burma S., Chen B.P., Chen D.J. Role of non-homologous end joining (NHEJ) in maintaining genomic integrity. DNA Repair (Amst) 2006, 5:1042-1048.
21. Adachi N., Suzuki H., Iiizumi S., Koyama H. Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193: implications for the repair of topoisomerase II-mediated DNA damage. J. Biol. Chem. 2003, 278:35897-35902.
22. Yang Q.S., Gu J.L., Du L.Q., Jia L.L., Qin L.L., Wang Y., Fan F.Y. ShRNA-mediated Ku80 gene silencing inhibits cell proliferation and sensitizes to gamma-radiation and mitomycin C-induced apoptosis in esophageal squamous cell carcinoma lines. J. Radiat. Res. (Tokyo) 2008, 49:399-407.
23. Chow T.Y., Alaoui-Jamali M.A., Yeh C., Yuen L., Griller D. The DNA double-stranded break repair protein endo-exonuclease as a therapeutic target for cancer. Mol. Cancer Ther. 2004, 3:911-919.
24. Tian X., Chen G., Xing H., Weng D., Guo Y., Ma D. The relationship between the down-regulation of DNA-PKcs or Ku70 and the chemosensitization in human cervical carcinoma cell line HeLa. Oncol. Rep. 2007, 18:927-932.
25. Li A.Y., Boo L.M., Wang S.Y., Lin H.H., Wang C.C., Yen Y., Chen B.P., Chen D.J., Ann D.K. Suppression of nonhomologous end joining repair by overexpression of HMGA2. Cancer Res. 2009, 69:5699-5706.